Replies to post #136154 on Biotech Values

[piggerpig]

One new thing I did get is that NVS decided that their MEK has reached POC based on undisclosed data - this was in answer to a question about that. They didnt realy say what POC means , but said obviously NVS is very pleased with what they are seeing and have made it a global priority with an agressive research scheduele

[mcbio]

I think, if nothing else, the market, for the moment at least, is acknowledging a company selling for 159ml with so many shots on goal(however questionable the odds per shot), that's functioning with close to a balanced budget.

To be fair, I don't think it's right to reference ARRY having a balanced budget given that they still have $86M in Deerfield debt, notwithstanding that it isn't due until 2015/2016. It's still a nice chunk. But, to their credit, they have cut costs a nice little bit and have a little more breating room to operate I do believe. Still think they may do an offering fairly soon, though ARRY also does have several assets they can potentially partner in due time and their track record has been good on this front.

I'm still holding here and I don't see that changing any time soon. The MEKs are still the main part to the story IMHO and there are important readouts this year. No guarantees on the readouts but I'm willing to risk holding on here given what I've seen so far in the clinic from the MEKs combined with ARRY's valuation.